Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$846M |
| 2 |
JD.com
JD
|
+$782M |
| 3 |
Dollar General
DG
|
+$647M |
| 4 |
Monster Beverage
MNST
|
+$324M |
| 5 |
NXP Semiconductors
NXPI
|
+$240M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Union Pacific
UNP
|
+$668M |
| 2 |
Mondelez International
MDLZ
|
+$528M |
| 3 |
Alibaba
BABA
|
+$457M |
| 4 |
TWTR
Twitter, Inc.
TWTR
|
+$409M |
| 5 |
CELG
Celgene Corp
CELG
|
+$403M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.97% |
| 2 | Consumer Discretionary | 16.01% |
| 3 | Technology | 12.95% |
| 4 | Communication Services | 12.43% |
| 5 | Financials | 9.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
PUT
BioMarin Pharmaceuticals
BMRN
$11.9B
| $16.4M | 0.02% |
120,000
| – | – |
|
|
ESPR
477
CALL
DELISTED
Esperion Therapeutics
ESPR
| $16.4M | 0.02% |
+200,000
| New | +$19.6M |
|
478
Seres Therapeutics
MCRB
$45M
| $16.2M | 0.01% |
+19,500
| New | +$17M |
|
479
Kinross Gold
KGC
$27.7B
| $16.1M | 0.01% |
6,947,373
+24,412
| +0.4% | +$58.2K |
|
480
Ocular Therapeutix
OCUL
$1.83B
| $16.1M | 0.01% |
766,279
+627,861
| +454% | +$15.6M |
|
481
ProQR Therapeutics
PRQR
$244M
| $16.1M | 0.01% |
966,433
+2,968
| +0.3% | +$55.9K |
|
|
AGTC
482
DELISTED
Applied Genetic Technologies Corporation
AGTC
| $16M | 0.01% |
1,041,823
+6,601
| +0.6% | +$127K |
|
483
Varonis Systems
VRNS
$4.67B
| $15.7M | 0.01% |
2,132,652
+157,443
| +8% | +$1.24M |
|
484
Paycom
PAYC
$7.88B
| $15.7M | 0.01% |
458,643
+15,702
| +4% | +$543K |
|
|
BLOX
485
DELISTED
Infoblox Inc
BLOX
| $15.6M | 0.01% |
+593,719
| New | +$15M |
|
|
AVDL
486
DELISTED
Avadel Pharmaceuticals
AVDL
| $15.3M | 0.01% |
720,960
+7,190
| +1% | +$129K |
|
|
THS
487
DELISTED
Treehouse Foods
THS
| $15.1M | 0.01% |
185,933
-326,352
| -64% | -$25.2M |
|
|
EPRS
488
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
| $15M | 0.01% |
2,630,942
+15,948
| +0.6% | +$109K |
|
|
TSRO
489
DELISTED
TESARO, Inc.
TSRO
| $14.9M | 0.01% |
252,674
+2,427
| +1% | +$139K |
|
|
KIN
490
DELISTED
Kindred Biosciences, Inc.
KIN
| $14.7M | 0.01% |
2,162,167
+14,985
| +0.7% | +$106K |
|
|
CELG
491
PUT
DELISTED
Celgene Corp
CELG
| $14.7M | 0.01% |
126,900
| – | – |
|
492
Madrigal Pharmaceuticals
MDGL
$12.6B
| $14.7M | 0.01% |
188,139
+1,363
| +0.7% | +$114K |
|
|
FEIC
493
DELISTED
FEI COMPANY
FEIC
| $14.7M | 0.01% |
177,023
+5,716
| +3% | +$456K |
|
|
DTEA
494
DELISTED
DAVIDsTEA Inc. Common Stock
DTEA
| $14.5M | 0.01% |
+673,864
| New | +$16.6M |
|
|
MPG
495
DELISTED
Metaldyne Performance Group Inc.
MPG
| $14.1M | 0.01% |
775,647
+4,059
| +0.5% | +$76.9K |
|
|
FCSC
496
DELISTED
Fibrocell Science Inc.
FCSC
| $14M | 0.01% |
177,002
+1,154
| +0.7% | +$77.7K |
|
|
INXN
497
DELISTED
Interxion Holding N.V.
INXN
| $13.8M | 0.01% |
500,753
-60,649
| -11% | -$1.8M |
|
498
PUT
Incyte
INCY
$25.4B
| $13.5M | 0.01% |
130,000
| – | – |
|
|
NXTM
499
DELISTED
NxStage Medical Inc.
NXTM
| $13.4M | 0.01% |
936,988
+360,316
| +62% | +$6.1M |
|
|
ESRX
500
CALL
DELISTED
Express Scripts Holding Company
ESRX
| $13.3M | 0.01% |
+150,000
| New | +$13.1M |
|
Similar funds
Jennison Associates's Q2 2015 Portfolio in Review
As of Q2 2015, Jennison Associates held 801 positions worth $109B, down 0.05% from $109B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Jennison Associates's Q2 2015 filing shows 92 new, 315 increased, 305 reduced and 72 closed positions. Its largest new stake was Regeneron Pharmaceuticals: 1,732,726 shares worth $884M. The largest sale was Union Pacific, an estimated $668M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Technology.
- Jennison Associates's largest Q2 2015 buy was Regeneron Pharmaceuticals: 1,732,726 shares worth $884M.
- Jennison Associates added most to JD.com in Q2 2015, an estimated $782M increase.
- Jennison Associates's biggest Q2 2015 reduction was Union Pacific, cutting an estimated $668M.
- Jennison Associates fully exited Perrigo in Q2 2015, selling an estimated $204M.
- Jennison Associates's ten largest holdings make up 21% of its $109B portfolio in Q2 2015.
- Jennison Associates opened 92 new positions and closed 72 in Q2 2015.
- Jennison Associates's portfolio value fell 0.05% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q2 2015, filed 3 Aug 2015.